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ABSTRACT
The clinical and biological relevance of a paraprotein that newly arises after 
allogeneic hematopoietic stem cell transplantation (allo-HSCT) in non-myeloma 
patients is unknown. In this study, the incidence, the course, and the clinical impact of 
paraproteins found after allo-HSCT were investigated in a cohort of 383 non-myeloma 
patients. Paraproteinemia after allo-HSCT was more frequent (52/383 patients, 14%) 
than the reported incidence of monoclonal gammopathy of unknown significance 
(MGUS) in age-matched healthy subjects and, in contrast to MGUS, did not correlate 
with age.  In most patients (32/52, 62%), the paraprotein appeared transiently within 
the first year after allo-HSCT with a median duration of 6.0 months. Post-allo-HSCT 
paraproteinemia was significantly associated with graft versus host disease (GvHD) 
and correlated with a survival benefit within the first year, but not after five years 
following allo-HSCT. Importantly, patients with post-allo-HSCT paraproteinemia did 
not progress into a plasma cell myeloma as observed for MGUS inferring a distinct 
pathogenic mechanism. Skewing of lymphocyte subpopulations and alterations in 
cytokine levels in GvHD may explain the expansion of a specific plasma cell subset in 
non-myeloma patients undergoing allo-HSCT. Our data suggests that paraproteinemia 
after allo-HSCT is a reactive phenomenon rather than the consequence of clonal 
plasma cell transformation.
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 63), pp: 106333-106341
INTRODUCTION
Paraproteins are abnormal immunoglobulins 
detected by immunofixation and protein electrophoresis. 
A monoclonal gammopathy of unknown significance 
(MGUS) is characterized by the production of a 
paraprotein by clonal, genetically aberrant plasma 
cells [1]. While the detection of a paraprotein per se is 
abnormal, its clinical relevance depends on the plasma 
cell mass and end organ damage. In healthy subjects, 
the incidence of paraproteinemia increases with age and 
confers an increased risk for the development of plasma 
cell myeloma [2]. IgG is the most frequent paraprotein 
subtype while the incidence of IgM and IgA paraproteins 
is significantly lower, but associated with a higher risk of 
transformation to plasma cell myeloma [3].
The appearance of paraproteins following 
allogeneic hematopoietic stem cell (allo-HSCT) and 
solid organ transplantation has been reported previously 
[4–9]. However, the clinical and prognostic relevance 
of post-transplantation paraproteinemia remains unclear. 
Factors reported to be associated with the development 
of paraproteinemia following allo-HSCT include an 
alemtuzumab-based conditioning regimen, reactivation of 
cytomegalovirus (CMV), and occurrence of chronic graft 
versus host disease (GvHD) [6, 7]. 
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In this large retrospective study, we investigated the 
development of post-allo-HSCT paraproteinemia in 383 
non-myeloma patients treated with allo-HSCT and aimed 
at identifying predictive factors and clinical parameters 
associated with this phenomenon. 
RESULTS
We analyzed a cohort of 383 non-myeloma 
patients who underwent allo-HSCT for the development 
of paraproteinemia after HSCT. Paraproteinemia was 
detected in 52/383 (14%) patients and was equally 
distributed among age groups (p = 0.723) (Figure 1A). 
Most paraproteins were of IgG subtype (39/52, 75%) 
with an equal distribution between kappa and lambda 
light chain expression (Figure 1B). An IgM paraprotein 
was found in 5/52 (9.6%) patients. In 8/52 (15.4%) cases, 
two paraproteins were detected in the same patient (IgG 
kappa/IgG lambda, IgM kappa/IgM lambda and IgG/IgM). 
However, no significant difference in clinical parameters 
(see below) and survival was observed between patients 
with one or two paraproteins (data not shown). Almost all 
paraproteins (50/52, 96%) detected by immunofixation 
were not quantifiable by protein electrophoresis due 
to the low level of paraprotein expression, and bone 
marrow histology did not reveal infiltration by plasma 
cell myeloma or lymphoma. In the majority of cases 
(40/52, 77%), paraproteinemia appeared within the first 
year after allo-HSCT and the median time to detection 
of a paraprotein was 6.0 months post-allo-HSCT (range: 
0.24–7.05 years, Figure 2). The majority of paraproteins 
(32/52, 62%) were transient with a median period of 
detection of 6.0 months (range 2.5–46.8 months). However, 
in 20/52 (38%) patients, the paraproteinemia persisted 
until death (n = 11) or the end of the observation period 
(n = 9). The median observation period of all patients with 
paraprotein was 37 months (range 5.4–137.1 months). The 
most frequent cause of death was relapse of the underlying 
disease (11 patients), while one patient died from GvHD. No 
evolution to plasma cell myeloma or B-cell lymphoma was 
observed in patients with post-allo-HSCT paraproteinemia. 
Accordingly, laboratory parameters associated with the 
development of plasma cell myeloma did not deteriorate 
between the first and the last detection of paraproteinemia 
(Supplementary Table 1 and Supplementary Figure 1).
To identify factors that may predict or be causative 
for paraprotein development following allo-HSCT we then 
correlated clinical parameters with the appearance of post-
allo-HSCT paraproteinemia. The majority of patients in the 
study were treated for acute leukemia, but no association 
was identified between the underlying disease and the 
appearance of paraproteins (260/383, 68%, Table 1). 
However, using a Chi-squared test and a log-linear model 
a significant association was identified between the 
detection of a paraprotein and a small group of patients 
with mature T-cell lymphoma, but not with other diseases 
(Table 1 and Figure 3A). 
The median age of patients with paraproteinemia 
was 45 years (Table 1) and paraproteinemia was not 
associated with gender (p = 0.299). In 12 patients, 
paraproteinemia occurred after the first year following 
allo-HSCT (Figure 2), but we did not find significant 
differences in clinical parameters and survival between 
patients with early (i.e. <12 months post-allo-HSCT) or 
late (i.e. >12 months post-allo-HSCT) paraproteinemia 
(data not shown). An increased incidence of post-
allo-HSCT paraproteinemia has been reported after 
alemtuzumab-based conditioning [6, 7]. In this study, 
only five patients obtained alemtuzumab as part of their 
conditioning regimen, but none of them developed 
paraproteinemia (Supplementary Table 2).  Furthermore, 
the conditioning regimen and anti-thymocyte globulin 
(ATG) pretreatment were not associated with the 
development of paraproteinemia in the binary logistic 
regression analysis in our study (p = 0.225). In addition, 
neither the hematopoietic stem cell source (p = 0.381), 
nor the type of donor (p = 0.127) or the reactivation 
of CMV (p = 0.494) had an impact on the appearance 
of paraproteinemia. Since none of the patients with 
paraproteinemia developed a clonal plasma cell disorder, 
we hypothesized that post-allo-HSCT paraproteinemia 
was the consequence of a perturbed immune system in 
patients with GvHD. Indeed, the χ2 test for independency 
and the binary logistic regression both revealed an 
association between paraproteinemia and GvHD 
(p = 0.034 and  p = 0.046, respectively, Table 1 and 
Figure 3B) supporting a causative role for GvHD in post-
allo-HSCT paraproteinemia. Finally, the Kaplan-Meier 
survival analysis showed a statistically significant survival 
benefit in the first year after allo-HSCT for patients with 
paraproteinemia (p = 0.017, HR = 0.27, CI = 0.08–0.86), 
which was not observed five years following allo-HSCT 
(p = 0.13, HR = 0.64, CI = 0.35–1.15) (Figure 4). 
DISCUSSION
In this retrospective study, we investigated 383 non-
myeloma patients treated with allo-HSCT and found a high 
incidence of post-allo-HSCT paraproteinemia compared to 
the incidence of MGUS in age-matched healthy subjects 
[3]. However, and in contrast to MGUS, none of the 
patients with paraproteinemia developed plasma cell 
myeloma or B-cell lymphoma during the observation 
period suggesting a distinct pathogenic mechanism. 
This hypothesis is also supported by the observation that 
62% of post-allo-HSCT paraproteins were only detected 
transiently in our cohort. In our study 3/4 patients with 
mature T-cell lymphoma developed paraproteinemia 
following allo-HSCT, a finding that needs to be validated 
in a larger cohort of patients. 
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Interestingly, we found a significant association 
between paraprotein development and the occurrence of 
GvHD as observed previously in a smaller cohort [6]. 
Disruption of B-cell homeostasis has been implicated in 
the pathogenesis of GvHD [10–12]. Patients with chronic 
GvHD (cGvHD) produce excessive levels of B-cell 
activating factor (BAFF) which promotes B-cell survival 
and maturation and is associated with the production of 
pre-germinal center B-cells and post-germinal center 
plasma-like cells in patients with cGvHD [13]. Moreover, 
increased levels of BAFF are associated with increased 
autoantibody production [14]. Therefore, altered B-cell 
homeostasis following allo-HSCT may lead to aberrant 
production of immunoglobulins in GvHD as observed in 
our study. In addition, increased generation of a T-follicular 
helper cell subset that produces high levels of IL-17 and 
Figure 1: Characterization of post-allo-HSCT paraproteinemia. (A) Number of patients with (black) and without (grey) 
paraproteins after allo-HSCT stratified according to the age range. (B) Post-allo-HSCT paraprotein subtypes. 
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IL-21 and promotes B-cell immunoglobulin secretion may 
contribute to production of paraproteins [15]. Alterations 
in T-cell subpopulations may also underlie paraprotein 
generation in patients receiving allo-HSCT following 
an alemtuzumab-conditioning as reported previously 
[6, 7]. Post-allo-HSCT paraproteinemia was significantly 
associated with a survival benefit during the first year 
following allo-HSCT, but not at later time-points. Since 
most paraproteins appeared transiently during the first 
year after allo-HSCT and correlated with the occurrence of 
GvHD post-allo-HSCT paraproteinemia may hint towards 
the presence of a graft versus leukemia effect, which could 
explain the survival benefit observed in the investigated 
cohort. 
In summary, our study investigates the largest non-
myeloma patient cohort to date treated by allo-HSCT 
for the development of paraproteinemia and suggests an 
association with GvHD. Importantly, post-allo-HSCT 
paraproteinemia is mostly transient and does not translate 
into development of plasma cell myeloma or lymphoma. 
Figure 2: Development of paraproteinemia over time. Each arrow represents the observation period over time of an individual 
patient with paraproteinemia in the study. The red bar indicates the presence of a paraprotein. Star, Cessation of ciclosporin A; Dot, 
Cessation of mycophenolate mofetil; Angled arrow, diagnosis of GvHD; Cross, death during observation period. 
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Table 1: Characteristics of patients with post-allo-HSCT paraproteinemia
Parameter No paraprotein detected Paraprotein detected p-value
Age (y)
Median 48 45
0.723
IQR 36.0–57.5 39.8–53.0
Gender (n, %)
Female 143 (43.2) 27 (51.9)
0.299
Male 188 (56.8) 25 (48.1)
Diagnosis (n, %)
ALL 46 (13.9) 9 (17.3)
0.047
AML 179 (54.1) 26 (50.0)
CLL 4 (1.2) 2 (3.8)
CML 24 (7.3) 5 (9.6)
HL 8 (2.4) 2 (3.8)
MBCN 20 (6.0) 1 (1.9)
MDS 18 (5.4) 2 (3.8)
MDS/MPN 4 (1.2) 0 (0.0)
MPN 18 (5.4) 2 (3.8)
MTCN 1 (0.3) 3 (5.8)
PID 5 (1.5) 0 (0.0)
SAA 4 (1.2) 0 (0.0)
Conditioning (n, %)
MAC 81 (24.5) 13 (25.0)
0.225
MAC+ATG 74 (22.4) 16 (30.8)
RIC 31 (9.4) 1 (1.9)
RIC+ATG 145 (43.8) 22 (42.3)
Donor (n, %)
MRD 157 (47.4) 21 (40.4)
0.127
MUD 135 (40.8) 29 (55.8)
Mismatched 29 (8.8) 1 (1.9)
Haploidentical 10 (3.0) 1 (1.9)
Stem cell source (n, %)
Bone marrow 50 (15.1) 11 (21.2)
0.381Peripheral blood 276 (83.4) 41 (78.8)
Cord blood 5 (1.5) 0 (0.0)
GvHD (n, %)
Acute 87 (29.9) 13 (25.0)
0.034
Chronic 68 (23.4) 18 (34.6)
Both 40 (13.7) 12 (23.1)
None 96 (33.0) 9 (17.3)
CMV (n, %)
Reactivation 69 (23.3) 15 (28.8)
0.494
No reactivation 227 (76.7) 37 (71.2)
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Future studies will determine the role of GvHD-associated 
paraproteinemia in the prediction of disease-free survival 
and investigate the involvement of specific lymphocyte 
subsets in the pathogenesis of this transient phenomenon. 
MATERIALS AND METHODS 
Patients
The study was approved by the local ethics 
committee (BASEC-Nr. 2016–01139). 383 patients who 
underwent allo-HSCT in the Division of Hematology at 
the University Hospital Zurich, Switzerland, between 
2004 and 2014 were retrospectively investigated for 
the development of post-allo-HSCT paraproteinemia. 
The following patients were excluded from the study; 
patients with plasma cell myeloma, autoimmune disease, 
paraproteinemia before allo-HSCT and patients without 
documented negative immunofixation prior to allo-HSCT. 
The observation period started with the date of the allo-
HSCT and ended December 31, 2015 or with the patient’s 
death. The patient characteristics are outlined in Table 1. 
Serum proteins electrophoresis measurement
Immunofixation and serum protein electrophoresis 
was performed before and regularly every 3 to 6 months 
after allo-HSCT. Proteins were separated on an agarose-
gel followed by immunoprecipitation in situ with 
monospecific antisera against heavy and light chains 
(EasyFix Interlab G26, Apteq Switzerland). The gels were 
interpreted by two independent laboratory technicians. 
Paraproteins were quantified by densitometry. For the 
purpose of the study, only monoclonal paraproteins 
detected by immunofixation were used for correlative 
studies. 
Conditioning regimen and GvHD prophylaxis
The conditioning regimens used in the study are 
outlined in Supplementary Table 2. GvHD prophylaxis for 
all patients consisted of intravenous ciclosporin A (CsA) 
until engraftment of donor hematopoiesis, followed by oral 
application with a target whole blood concentration of 150–
250 μg/l. Patients with myeloablative conditioning (MAC) 
IQR, interquartile range; Diagnoses: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic 
lymphocytic leukemia; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; MBCN, mature B-cell neoplasms; 
MDS, myelodysplastic syndrome; MDS/MPN, myelodysplastic/myeloproliferative neoplasms; MPN, myeloproliferative 
neoplasms; MTCN, mature T-cell neoplasms including Sézary syndrome and mycosis fungoides; PID, Primary 
immunodeficiency; SAA, severe aplastic anemia. Conditioning regimens: MAC, myeloablative conditioning; MAC+ATG, 
myeloablative conditioning with anti-thymocyte globulin (Fresenius); RIC, reduced intensity conditioning; RIC+ATG, 
reduced intensity conditioning with anti-thymocyte globulin. Donor: MRD, mached related donor; MUD, matched 
unrelated donor (10/10); Mismatched, non-HLA-identical donor; Haploidentical, haploidentical family donor; GvHD, 
graft versus host disease; CMV, cytomegalovirus.
Figure 3: Association of post-allo-HSCT paraproteinemia and clinical parameters depicted in mosaic plots. 
(A) Association of post-allo-HSCT paraproteinemia and diagnoses according to Table 1. The mosaic plots graphically display data on a log-
linear scale. Each horizontal box from left to right represents a diagnosis as presented in Table 1: 1) ALL, acute lymphoblastic leukemia, 
2) AML, acute myeloid leukemia, 3) CLL, chronic lymphocytic leukemia, 4) CML, chronic myeloid leukemia, 5) HL, Hodgkin lymphoma, 
6) MBCN, mature B-cell neoplasms, 7) MDS, myelodysplastic syndrome, 8) MDS/MPN, myelodysplastic/myeloproliferative neoplasms, 
9) MPN, myeloproliferative neoplasms, 10) MTCN, mature T-cell neoplasms including Sézary syndrome and mycosis fungoides, 11) PID, 
Primary immunodeficiency, 12) SAA, severe aplastic anemia. The blue box indicates a significant association for patients with mature T 
cell neoplasms (MTCN) and post-allo-HSCT paraproteinemia. The small open dots indicate that no patient was identified in the subgroup. 
(B) Association of post-allo-HSCT paraproteinemia and GvHD. 
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Figure 4: Kaplan-Meier survival analysis for patients with (dashed red line) or without (black line) post-allo-HSCT 
paraproteinemia. (A) Cumulative survival one year after allo-HSCT. (B) Cumulative survival five years after allo-HSCT. 
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received three to four doses of methotrexate (MTX, 15 mg/
m2) on day 1 and 10 mg/m2 on day 3, 6 and 11 after allo-
HSCT. In addition, mycophenolic mofetil (MMF, 2 g/d) was 
given to patients with reduced intensity conditioning (RIC) 
until day 28 in related donor and day 56 in unrelated donor 
allo-HSCT. In the absence of GvHD immunosuppression 
was tapered starting at day 100 following allo-HSCT. 
Graft versus host disease
Acute (aGvHD) and chronic GvHD (cGvHD) were 
defined according to the National Institutes of Health 
Consensus Development Project criteria [16]. GvHD of 
the eye and skin was diagnosed clinically. GvHD of the 
intestine and the liver was documented by histological 
analysis. Documentation on GvHD development was not 
available in 40 patients.   
Cytomegalovirus reactivation 
CMV copy number quantification was performed 
twice weekly by polymerase chain reaction for the first 
120 days following allo-HSCT. CMV reactivation was 
defined as a CMV copy number increase above 1000/µl. 
Patients with documented CMV reactivation obtained 
antiviral treatment. Documentation on CMV reactivation 
was not available in 35 patients.   
Statistical analysis
All statistical analyses were performed using the 
statistical software environment R v.3.2.2 (www.r-project.
org) with the R packages tableone 0.8.1, compareGroups, 
vcd, survival and survminer. Comparison of categorical 
data between groups was performed with the Chi-squared 
test.  Furthermore, categorical data for paraprotein, 
diagnosis and GvHD were analyzed using log-linear 
modeling and were visualized by mosaic plots.  For the 
estimation of survival curves Kaplan-Meier methods were 
used. Comparison of overall survival between groups of 
patients with or without paraproteinemia was performed 
using the log-rank test and Cox’s proportional hazard 
model (Cox regression).
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